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Background: Glycyrrhizae Radix (GR) is a Korean traditional herb medicine that is widely-used in clinical health care.
The clinical functions of GR include relief of toxicity, anti-cancer, regulating blood cholesterol and anti-inflammation.
This study investigated the role of GR on ulcerative colitis in a dextran sulfate sodium (DSS)-induced mouse model
of colitis.
Method: Western blot analysis and enzyme-linked immunosorbent assay (ELISA) analyses were done on male
BALB/c mice administered 5 % DSS during the experimental period. Ethanol extracts of GR were orally administered
at same time daily to control mice. The severity of colitis was measured by body weight change and colon length.
Result: DSS-treated mice displayed weight loss and shortened colon length compared with control mice. Mice
were administered GR showed less weight loss and longer colon length than the DSS-treated group. Inflammatory
cytokines were decreased by GR treatment. Treatment also reduced DSS-induced microscopic damage to colon
tissue. GR regulated the phosphorylation of transcription factors such as NF-κB p65 and IκB α.
Conclusions: GR has beneficial effects in a colitis model. GR might be a useful herb medicine in the treatment of
ulcerative colitis.
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Ulcerative colitis (UC) is a chronic and relapsing
inflammatory disease characterized by dysregulation of
the immune function response and imbalanced release
of cytokines and unresolved inflammatory progress
associated with intestinal mucosa [1, 2]. The inflamma-
tion reaction may be initiated by proinflammatory cyto-
kines [3]. Patients with bowel disease have increased
interleukin-(IL) 6 in the intestinal mucosa and tumor
necrosis factor-alpha (TNF-α) in the blood and colon
tissue. Immune cells (T cells, intestinal epithelial cells,
macrophages) secrete various cytokines including TNF-α,
IL-1, IL-6, IL-8 and interferon-gamma (IFN-γ), which
regulate the inflammatory response in UC. Elevated levels
of cytokines have also been implicated in the pathogenesis
of bowel disease [4, 5].* Correspondence: jongsik.jin@jbnu.ac.kr
1Department of Oriental Medicine Resources, Chonbuk National University,
79 Gobongro, Iksan, Jeollabuk-do 570-752, Republic of Korea
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeBlocking the generation of inflammatory cytokines is
an area of robust research in ulcerative colitis therapy
[6]. In chronic colitis, inflammation extends into the
colon muscle layer with acute manifestations, followed
by an asymptomatic period and a relapse that occurs
months or even years later [7]. UC affects the rectum
and extends in a retrograde manner with extensive areas
of superficial lesions [8]. The pathogenic factors of UC
are unclear, but heredity, immune system dysfunction,
and dietary habits could be influential [9].
Dextran sulfate sodium (DSS)-induced colitis is a
suitable mice model characterized by the morphologic-
ally and biochemically. DSS induces bloody stools,
ulcerations, epithelial injury and infiltration of inflam-
matory cells [10]. Histologically, DSS influences crypt
abscesses and epithelioglandular hyperplasia in mice.
DSS induced crypt architecture, disappearance of crypts
and inflammatory infiltration. During DSS colitis, inter-
cellular distance of mucosal cells in crypt and vascular
endothelial cell was increased [11]. These colon condi-
tions are similar to acute and chronic UC in humans.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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and affects the integrity of the mucosal barrier [12].
Thus, the DSS-induced colitis model is especially suit-
able to study mechanism of inflammatory colitis.
Cyclooxygenase is a constitutive enzyme that catalyzed
the production of prostaglandins (PGs), which protect
the stomach from damage. COX-2 is induced by inflam-
matory stimuli, such as cytokines, and also catalyzed PG
production that contributes to inflammation-related
swelling [13]. COX-2 and PGE2 levels are raised in the
inflamed mucosa of patients with UC [14]. So, to eluci-
date reduction of COX-2 and PGE2 shows another
pathway to ameliorate inflammation.
Glycyrrhiza Uralensis is a medical plant grown in
Europe and Asia. It has been used as a herbal medicine
respiratory system and gastrointestinal tract medicine
[15]. Glycyrrhizae Radix (GR) has been traditionally
used for treatment of cough, anti-allergy and bowel dis-
ease [16]. GR possesses various bioactive constitutents
that include saponins, flavonoids and coumarins [17].
Constituents of GR have anti-inflammatory effects in
lipopolysaccharide-stimulated macrophage. Glycyrrhi-
zin suppressed nitric oxide, TNF-α and PGE2 levels in
LPS-stimulated macrophage. Glycyrrhetic acid and
glycyrol have anti-inflammatory effect by regulation of
NF-κB pathway in LPS-treated RAW264.7 macro-
phage through inhibition of inflammatory cytokines
such as IL-6, IL-1β, and TNF-α. Also glycyrol regu-
lates COX-2 and iNOS expression in LPS-treatment
[18]. These results supposed that GR has anti-
inflammatory effects in vitro. Therapeutic activities
attributed to GR include anti-cancer, anti-diabetes,
antioxidant and anti-inflammation [19]. However, it is
unknown whether GR or its constitutents can regulate
intestinal inflammation.
To explore the potential of GR as a useful therapeutic
in UC, we examined its effects on DSS-induced colitis
in a mouse model. The goals were to evaluate the effect
of GR on clinical signs including weight loss, colon
shortening, diarrhea and gross bleeding, and to investi-
gate the role of GR on inflammatory mediators in DSS-
treated mice.Table 1 Criteria for disease activity index
Score Weight loss (%) Stool Consistency Bloodstain or gross Bleeding
0 None Normal Negative
1 1-5 Loose stool Negative
2 5-10 Loose stool Positive
3 10-15 Diarrhea Positive
4 >15 Diarrhea Gross bleedingMethods
Preparation of GR
GR purchased from Humanherb (kyuong San, Korea).
GR extract was prepared by decocting with 70 % ethanol
for 3 h (100 g/L). The solvent ethanol was filtered and
allowed to evaporate using a rotary evaporator at a
temperature of 40–45 °C. The yield of dried extract
was 3.022 %. The extract was diluted in 0.9 % saline
and filtered through a 0.22 μm syringe filter (HYUNDAI
Micro, Seoul, Korea).Mice
Male BALB/c, 6-week-old mice obtained from SAMTACO
(Osan, Kyungki-Do, Korea) were acclimatized in a specific
pathogen-free environment under controlled conditions
(22 ± 2 °C with a 12 h light/dark cycle) for a week. The mice
were housed in five colony cages with six mice per cage.
Experimental design
All experimental protocols (CBNU2015-089) were ap-
proved by the Committee on the Care of Laboratory
Animal Resources, Chonbuk National University and
were conducted in accordance with the Guide for the
Care and Use of Laboratory Animals. Acute colitis was
induced by administering drinking water containing 5 %
(w/v) DSS (MP Bio, Santa Ana, CA, USA) to mice for
10 days. Thirty mice were weighted before the experi-
ment, and were divided into five groups with six mice
per group. Group 1 comprised untreated mice. Mice in
group 2 received DSS. In group 3 and group 4, mice
with induced colitis were treated with GR 100 mg/kg or
50 mg/kg, respectively. In group 5, mice with induced
colitis were treated with 50 mg/kg 5-aminosalicylic acid
(5-ASA; Sigma-Aldrich, St. Louis, MO, USA) as the ref-
erence drug. Mice were checked daily for body weight,
stool consistency and the presence of gross bleeding. GR
was diluted with purified water and orally administered
once a day during the 10 days of DSS treatment, after
which the mice were sacrificed.
Disease Activity Index (DAI)
Intestinal disease activity was assessed based on the
weight loss, presence of diarrhea accompanied by blood
and mucus, and colonic shortening [20]. DAIs were cal-
culated by scoring weight loss, diarrhea and rectal bleed-
ing based on the scoring system shown in Table 1 that
was previously described by Murthy et al. [21]. Weight
loss was defined as the difference between initial and
final weights, and diarrhea as the absence of fecal pellet
formation and the presence of continuous fluid fecal
material in the colon. Rectal bleeding was assessed
based on the presence of diarrhea containing visible
blood and on the presence of gross rectal bleeding. DAI
values were calculated as {(weight loss score) + (diar-
rhea score) + (rectal bleeding score)}/4. The DAI was
Table 2 Criteria for assessment of microscopic rectal damage
Score Remarks
0 Normal colonic mucosa
1 Loss of one-third of the crypts
2 Loss of two-third of the crypts
3 Lamina propria covered with single layer of epithelial cells with
mild inflammatory cell infiltration
4 Erosions and marked inflammatory cell infiltration
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col. The clinical parameters used in the present study
were chosen to represent the subjective clinical symp-
toms observed in human UC.
Cytokine assays
Levels of IL-6 and TNF-α in the serum and tissue were
measured using an enzyme-linked immunosorbent assay
(ELISA), as previously described [22]. Briefly, 96-wellFig. 1 Effect of Glycyrrhizae Radix (GR) on dextran-sulfate-sodium (DSS)-ind
by administering 5 % DSS in the drinking water for 10 days. Over the sam
5-aminosalicylic acid (5-ASA; 50 mg/kg) were given orally daily. a Body w
Weight changes are given by percentage (%). b Disease activity index sco
Data were analyzed by Tukey post hoc test (#P < 0.05 versus control andplates (SPL Life Science, Seoul, Korea) were coated with
100 μL of anti-mouse monoclonal antibody (1.0 mg/mL
at pH 7.4 in phosphate buffered saline [PBS]) and incu-
bated overnight at 4∘C. After additional washes, 50 μL of
sample, or IL-6 and TNF-α (BD Bioscience, San Diego,
CA, USA) standard was added and incubated at room
temperature for 2 h. Plates were washed and 0.2 μg/mL
of biotinylated anti-mouse antibody was added and in-
cubated at room temperature for 2 h. After washing,
avidin-peroxidase (Sigma-Aldrich, St. Louis, MO, USA)
was added and plates were incubated for 30 min at 37∘C.
The plates were then washed again and (2,2′-azino-bis [3-
ethylbenzothiazoline-6-sulfonic acid]-diammonium salt)
substrate (BD Bioscience, San Diego, CA, USA) was
added. Color development was measured at 405 nm using
an automated microplate ELISA reader (Molecular
Devices, Sunnyvale, CA, USA). Standard curves were pre-
pared using serial dilutions of recombinant antibody (BD
Bioscience, San Diego, CA, USA). Protein concentrationsuced clinical signs. Ulcerative colitis was induced in male BALB/c mice
e period, GR (25 mg/kg, 50 mg/kg) and the reference compound
eight was measured at the same time on the experimental days.
re in the five study groups. Values represent mean ± S.E.M. (n = 6).
*P < 0.05 versus DSS alone)
Fig. 2 Effect of GR on DSS-induced colon shortening. Ulcerative colitis was induced and GR and 5-ASA administered as described in the legend
to Fig. 1. Colon length steadily shortened in mice receiving DSS. a Colon was harvested on day 10, and colon lengths were measured. b Colon
lengths in the five groups. Values represent mean ± S.E.M (n = 6). Data were analyzed by Tukey post hoc test (#P < 0.05 versus control and
*P < 0.05 versus DSS alone)
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assay reagent (Sigma-Aldrich, St. Louis, MO, USA).
Western blot
The end of experiment, Mice were sacrificed and the
section of colons (5–8 mm) were dissected and flushed
with PBS. Distal colons were homogenized in lysis buffer
(iNtRON Biotech, Republic of Korea) and centrifuged at
16,582 g for 5 min. The supernatants were transferred to
fresh tubes and protein concentrations were determined
using BCA protein assay reagent (Sigma-Aldrich, St.
Louis, MO, USA). Lysates (50 μg protein) were separated
by 10 % SDS-PAGE and transferred to membranes
(Amersham Pharmacia Biotech, Piscataway, NJ, USA),
which were blocked with 5 % skim milk in 0.05 % PBS-
Tween-20 (PBST) for 1 h at room temperature. Mem-
branes were incubated overnight with primary antibodies
against phospho-extracellular signal regulated kinase
(pERK), phospho-3-Jun, N-terminal kinase (p-JNK),p38 (Cell Signaling technology, Danvers, MA, USA)
and glyceraldehyde-phosphate dehydrogenase (GAPDH)
(Thermo scientific, Waltham, MA, USA) and washed three
times with PBST. Blots were incubated with secondary
antibody for 1 h at room temperature. Antibody-specific
proteins were visualized using an enhanced chemilumines-
cence detection system (Amersham, Newark, NJ, USA).
Protein densities were quantified by densitometry.
Histological processing
Mice were sacrificed at the end of the experiment. The en-
tire colon was dissected and flushed with ice-cold PBS.
Sections of rectums were taken and fixed in 10 % neutral-
buffered formalin (Sigma-Aldrich) for 24 h at room
temperature and embedded in paraffin to provide sections
for histological evaluation. Severity of colitis was evaluated
in sections stained with Hematoxylin and Eosin (H&E;
Muto Pere Chemicals, Tokyo, Japan and Sigma-Aldrich)
by two independent observers blinded to the experimental
Fig. 3 Effect of GR on levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in DSS-induced colitis. Ulcerative colitis was induced
and GR and 5-ASA administered as described in the legend to Fig. 1. Cytokine production was determined by ELISA. a IL-6 production in mouse
serum at day 10. b TNF-α production in mouse serum at day 10. c IL-6 production in colon tissue. d TNF-α production in colon tissue. Values
represent mean ± S.E.M. (n = 6). Data were analyzed by Tukey post hoc test (#P < 0.05 versus control and *P < 0.05 versus DSS alone)
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moto et al. [23] summarized in Table 2. Mucosal damage
was scored as 0–4 based on the loss of crypt (mucosa) and
infiltration of inflammatory cells (maximum score = 4).
PGE2 assay
Distal colons were homogenized in lysis buffer (iNtRON
Biotech, South Korea), and centrifuged at 16,582 g for
5 min. PGE2 levels were quantified using immunoassay
kits according to the manufacturer’s instructions (Enzo
Life Science, East Farmingdale, NY, USA).
Identification of constituents of GR extract
GR extract lycyrrhizae was dissolved in methanol
(1 mg/ml). Glycyrrhizin and glycyrrhetic acid (Tokyo
Chemical Industry, Tokyo, Japan) were dissolved in
methanol for high-performance liquid chromatography
(HPLC) analysis. HPLC was performed on a Waters
2695 separation module (Waters, Milford, MA, USA)
coupled with a model 2487 dual λ absorbance detector(Waters) under the following conditions: column, TSK-gel
ODS-80Ts (4.6 mm × 150 mm; Tosoh Co., Tokyo, Japan);
mobile phase, 0.1 % formic acid (solvent system A) and
acetonitrile (solvent system B) in a gradient mode (B from
30 to 60 % in 15 min, B from 60 to 100 % from 15 to
30 min, B 100 % from 30 to 40 min); flow rate, 0.5 ml/min;
temperature, 30 °C and ultraviolet wavelength of 254 nm.
Statistical analysis
All results are presented as the mean ± S.E.M. Results
were analyzed using Graph Pad Prism version 5.0 pro-
gram (Graph Pad Software, Inc, La Jolla, CA, USA).
One-way analysis of variance with Tukey post hoc test
was used to determine statistically significant differences.
P <0.05 was considered significant.
Result
Effects of GR on clinical signs in DSS-induced colitis
DSS caused a decrease in body weight (Fig. 1a) and colon
length (Fig. 2a and b) at day 7 by 17.1 and 40.8 %
Fig. 4 Efect of GR on transcription factors in DSS-induced colitis. Ulcerative colitis was induced and GR and 5-ASA administered as described in
the legend to Fig. 1. a Phosphorylation of IκB α and phosphorylation of NF-κB were assayed by Western blot. b Relative ratio of phospho-IκB α
and NF-κB p65 calculated using an image analyzer. c Relative ratio of phospho-NF-κB and NF-κB p65 calculated using an image analyzer. Values
represent mean ± S.E.M. (n = 6). Data were analyzed by Tukey post hoc test (#P < 0.05 versus control and *P < 0.05 versus DSS alone)
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5-ASA alleviated the DSS effects on body weight loss and
colon shortening (Figs. 1a, 2a and b). GR also attenuated
the DSS-mediated increase in DAI scores (Fig. 1b).Effect of GR on IL-6 and TNF-α levels in DSS-induced UC
Serum IL-6 level was significantly higher in the DSS
treatment group (85.403 ± 10.719 pg/mL) than in the
control group (9.44 ± 0.942 pg/mL). IL-6 levels were lower
in the GR groups (25 mg/kg; 63.620 ± 7.942 pg/mL,
50 mg/kg; 36.143 ± 6.652 pg/mL) (Fig. 3a). The serum
TNF-α level was also increased in the DSS treatment
group (828.623 ± 110.387 pg/mL) compared to control
group (95.786 ± 11.485 pg/mL), but was lower in the GR
groups (50 mg/kg; 391.052 ± 63.914 pg/mL) (Fig. 3b). In
addition, tissue IL-6 and TNF-α levels were significantly
higher in the DSS treatment group (524.809 ± 28.643,
5648.749 ± 395.143 pg/mL) than in the control group
(61.640 ± 9.275, 1316.768 ± 156.371 pg/mL), but were
significantly decreased by GR (25 mg/kg; 241.031 ±31.794, 3258.119 ± 502.022 pg/mL, 50 mg/kg; 127.148
± 16.579, 2303.215 ± 90.442 pg/mL) (Fig. 3c and d).Effect of GR on transcription factors in
DSS-induced colitis
Nuclear factor-kappa B (NF-κB) is a important transcrip-
tion factor of inflammation reactions [24]. The effect of
GR on the activation of NF-κB was investigated. Phos-
phorylation of IκBα and NF-κB in the colon tissue was
inhibited by GR treatment (Fig. 4).Effect of GR on COX-2 and PGE2 abundance in
DSS-induced colitis
The effects of GR on COX-2 expression in colon tissues
were explored using Western blot analysis. DSS markedly
induced COX-2 expression in colon tissue versus control
group, but increased COX-2 expression was significantly
reduced by GR administration (Fig. 5a). Relative expres-
sion levels of COX-2 are presented in Fig. 5b. COX-2 cata-
lyzed PGE2 biosynthesis, and we examined whether GR
Fig. 5 Effect of GR on COX-2 and PGE2 abundance in DSS-induced colitis. Ulcerative colitis was induced and GR and 5-ASA administered as de-
scribed in the legend to Fig. 1. COX-2 levels were determined by Western blot analysis, and PGE2 levels using PGE2 assay kits. a Western blot ana-
lysis was used to determine COX-2 levels in colonic tissues. Data shown are representative of three independent experiments. b COX-2/GAPDH
ratios were determined by densitometry. c PGE2 production in colonic tissues. Values represent mean ± S.E.M. (n = 6). Data were analyzed by
Tukey post hoc test (#P < 0.05 versus control and *P < 0.05 versus DSS alone)
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and this increase was significantly inhibited by GR admin-
istration (Fig. 5c).
Effects of GR on epithelial injury in DSS-induced colitis
Mucosal thickness is regarded as a parameter of normal
mucosal condition. DSS caused epithelial injury and in-
filtration of inflammatory cells, including mast cells [25].
We observed histopathological changes of colon tissue
between DSS-treatment and control groups. And then
examined the effect of GR treatment. GR treatment at-
tenuated these effects induced by DSS treatment
(Fig. 6a). GR treatment also reduced the DSS-mediated
microscopic damage to the colonic tissue (Fig. 6b).
Identification of GR constituents
When standards compounds were analyzed by HPLC, the
retention times of glycyrrhizin and glycyrrhetic acid were19.5 and 29.8 unit, respectively. The two compounds were
detected in GR extracts (Fig. 7). Quantitative analysis of
glycyrrhetic acid indicated a concentration of 0.027 mg/g
in the extract.Discussion
Inflammatory bowel disease (IBD) including Crohn’s dis-
ease and UC is a chronic relapsing intestinal inflammatory
disorder. Even if the pathogenic mechanism of IBD is
barely understood, recent evidence suggests that deviant
immune responses results in IBD symptoms [26–29]. UC
symptoms can include weight loss and bloody diarrhea
[30]. Immune modulators, such as sulfasalazine and glu-
cocorticosteroids, have been broadly used for therapy for
UC [31]. These therapies can cause adverse effects like
vomiting, anemia and generalized edema. Thus, interest
has grown in the use of traditional herbal medicines for
Fig. 6 Effect of GR on epithelial injury in DSS-induced colitis. Ulcerative colitis was induced and GR and 5-ASA administered as described in
the legend to Fig. 1. a Paraffin sections of colonic tissue were stained with hematoxylin and eosin observed by microscope (100× and 400×).
b Microscopic scores. Values represent mean ± S.E.M. (n = 6). Data were analyzed by Tukey post hoc test (#P < 0.05 versus control and *P < 0.05
versus DSS alone)
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viduals per 100,000 people are diagnosed annually with
UC [33].
There are over the 20 animal models of colitis. DSS-
induced colitis is one of the most suitable experimental
models [34]. Using this model, we presently demonstrateFig. 7 HPLC elution profile of GR extractthat GR alleviates clinical signs of UC (weight loss, colon
shortening, diarrhea and occult/gross bleeding) (Figs. 1
and 2).
IL-6, TNF-α and IFN-γ are pathogenic mediators of
murine colitis [35, 36]. In IBD, immune cells including
T lymphocytes and macrophages secrete inflammatory
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cells modulate the balance between pro- and anti-
inflammatory cytokines. IL-6 and TNF-α expression is
elevated in the rectal mucosa of UC patients [37].
Presently, GR suppressed the DSS-induced increase in
IL-6 and TNF-α in mouse serum and tissues (Fig. 3).
In the inflammation reaction, COX-1 protein activity
rarely changes, but COX-2 production dramatically in-
creases, leading to the increased production of PGs [38].
Among the PGs, PGE2 is increased in the intestines of IBD
patients [39]. 5-ASA is used to treat IBD by inhibiting
COX-2 activation [40]. COX-2 and PGE2 play key role as
mediators in UC. Presently, GR inhibited the DSS-induced
activation of COX-2 and PGE2 (Fig. 5). The results suggest
that the anti-inflammatory effect of GR is attributable to
the regulation of COX-2 in DSS-induces colitis. We also
found that GR reduced epithelial injury and inflammatory
cell infiltration into colon tissue (Fig. 6).
Pro-inflammatory mediators, such as inflammatory
cytokines and chemokines are controlled by the activity
of transcriptional factors. The activation of NF-κB is
important in the pathogenesis of IBD [41–43]. DSS-
induced IκBα phosphorylation and phosphorylation of
NF-κB p65 in colonic tissues were suppressed by GR
treatment. These results suggested that GR can inhibit
the activation of transcription factors in UC.
Along with IL-6, TNF-α, COX-2 and NF-κB p65
phosphorylation, inflammation related factors including
caspases and mitogen-activated protein kinases affect
clinical signs [44]. Further investigation of GR effects
on colitis is needed to clarify the discrepancy.
GR is used as a traditional herbal medicine in many
Asian countries. Glycyrrhizin is the principal component of
GR, and has been used for treatment of liver disease,
allergic reaction and gastric ulcers [45]. Glycyrrhetic acid is
another component, which has an anti-inflammatory effect
on lipopolysaccharide-induced liver injury and inhibition of
hepatic lipotoxicity [46]. These compounds might be useful
for the prevention of inflammatory disease.
In summary, the anti-inflammatory activities of GR
were as effective as those of 5-ASA. GR may inhibit in-
flammation by regulating the inflammatory mediators
COX-2 and NF-κB. GR might be a useful therapeutic
agent for the treatment of inflammatory diseases.
Conclusions
GR extract reduces the clinical signs and levels of in-
flammatory mediators in DSS-induced colitis in mice.
GR extract suppresses PGE2 production. This study pro-
vides experimental evidence to show that GR might be a
useful therapy in the treatment of UC.
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